RXRX:NSD-Recursion Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 9.38

Change

+0.04 (+0.43)%

Market Cap

USD 2.31B

Volume

5.20M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
REGN Regeneron Pharmaceuticals Inc

+8.81 (+0.85%)

USD 126.22B
VRTX Vertex Pharmaceuticals Inc

+1.39 (+0.30%)

USD 120.00B
ALNY Alnylam Pharmaceuticals Inc

+1.84 (+0.67%)

USD 35.01B
ARGX argenx NV ADR

-24.43 (-4.45%)

USD 32.83B
MRNA Moderna Inc

+0.29 (+0.46%)

USD 25.25B
BGNE BeiGene Ltd

+5.81 (+2.81%)

USD 22.45B
SMMT Summit Therapeutics PLC

+0.17 (+0.75%)

USD 17.92B
RPRX Royalty Pharma Plc

+0.54 (+1.95%)

USD 16.34B
UTHR United Therapeutics Corporatio..

-1.79 (-0.50%)

USD 15.71B
PCVX Vaxcyte Inc

-2.02 (-1.78%)

USD 14.50B

ETFs Containing RXRX

ARKG 6.46 % 0.75 %

N/A

N/A
ARKG:LSE ARK Genomic Revolution UC.. 6.28 % 0.00 %

+0.03 (+0.53%)

USD 3.09M
ARCG:LSE ARK Genomic Revolution UC.. 6.28 % 0.00 %

+0.30 (+0.53%)

USD 3.03M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.87% 60% D- 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.87% 60% D- 46% F
Trailing 12 Months  
Capital Gain 26.08% 79% B- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 26.08% 79% B- 81% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -11.33% 44% F 25% F
Dividend Return -11.33% 44% F 25% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 37.75% 72% C 48% F
Risk Adjusted Return -30.01% 40% F 26% F
Market Capitalization 2.31B 90% A- 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector